Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 12/20 | 0.62 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938753 | 0.86 | KDM4E (0.50) | SCDKDM4E | |
| SCHEMBL938209 | 0.86 | SCD (0.69) | SCDDCTPP1 | |
| SCHEMBL937224 | 0.85 | SCD (0.66) | SCDDCTPP1 | |
| SCHEMBL5275966 | 0.82 | SCD (0.57) | SCDDCTPP1HCRTR1HCRTR2KDM4E | |
| SCHEMBL936628 | 0.82 | SCD (0.65) | SCDDCTPP1 | |
| SCHEMBL2760687 | 0.79 | SCD (0.54) | SCDDCTPP1HCRTR1HCRTR2 | |
| SCHEMBL3405929 | 0.79 | KDM4E (0.57) | SCDKDM4E | |
| SCHEMBL27633595 | 0.78 | SCD (0.60) | SCDDCTPP1 | |
| SCHEMBL2760778 | 0.78 | SCD (0.55) | SCDHCRTR1HCRTR2KDM4E | |
| SCHEMBL939044 | 0.78 | ALDH1A1 (0.48) | SCDDCTPP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042895-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2016-07-13 | — | — | EP | disclosed |
| EP-2316827-B1 | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2016-01-27 | — | — | EP | disclosed |
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | disclosed |
| US-7964591-B2 | Pyridazine derivatives and their use as therapeutic agents | NOVARTIS PHARMA AG (CH) | 2011-06-21 | — | — | US | disclosed |
| EP-2316827-A1 | Piperazine derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| US-20100311763-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | NOVARTIS PHARMA AG (US) | 2010-12-09 | — | — | US | disclosed |
| EP-2257291-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | Xenon Pharmaceuticals Inc. (CA) | 2010-12-08 | — | — | EP | disclosed |
| US-7759348-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-07-20 | — | — | US | disclosed |
| US-7754711-B2 | Antidiabetic agents; disease of glucose tolerance; insulin resistance; obesity; dyslipidemia; metabolic disorders; liver disorders | XENON PHARMACEUTICALS INC. (CA) | 2010-07-13 | — | — | US | disclosed |
| WO-2009106991-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-09-03 | — | — | WO | disclosed |
| US-20080280916-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-7335658-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-02-26 | — | — | US | disclosed |
| EP-1851205-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006086447-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | disclosed |
| EP-1648874-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-04-26 | — | — | EP | disclosed |
| US-20060009459-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | SCD 21/4885DCTPP1 2887/4885HCRTR1 2180/4885 |
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | PRXL2A, CUTA, MC1R | SCD 52/4885DCTPP1 2739/4885HCRTR1 1551/4885 |
| US-20080280916-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MC1R, CASP9, PRDX5 | SCD 19/4885DCTPP1 2877/4885HCRTR1 1232/4885 |
| US-20100311763-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MC1R, CASP9, PRDX5 | SCD 19/4885DCTPP1 2877/4885HCRTR1 1232/4885 |
| US-20060009459-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, C3AR1 | SCD 24/4885DCTPP1 3053/4885HCRTR1 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.